Data from EMC - Curated by Toby Galbraith - Last updated 16 March 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Airway Disease

The Airway Disease Learning Zone is an area where you can access the information about VisionAir and see video presentations from the forum. The Inhalation Technology page features a video presentation from the live broadcast presented by key faculty.

Visit Airway Disease

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting.

+ 3 more

Visit Bedwetting

Related Content

More information

Category Value
Agency product number EMEA/H/C/004085
Orphan designation No
Date First Approved 13-02-2017
Type POM
Marketing authorisation holder Eli Lilly Nederland B.V.